GFPC 03-2013 / FLARE
PROTOCOL FLARE /GFPC 03-2013
A multicenter randomized phase III study comparing second-line treatment with chemotherapy associated or not to erlotinib in NSCLC patients with secondary resistance to TKI-EGFR
Synopsis français FLARE V4 20140916 last